Huntington Neurosciences Clinical Trials
Research is an important component of the comprehensive care capabilities at the Huntington Hospital Neurosciences Stroke Center. Through clinical research, or clinical trials, we are able to explore and assess whether potentially beneficial therapies can lead toward better stroke outcomes, establishing new treatment protocols, improving patient quality-of-life and many other benefits.
Current trials open to enrollment:
Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours
ABSTRACT: It is hoped the medication will regenerate and protect the brain from further tissue injury. The study is being conducted in conjunction with the stroke center at UCLA. Huntington Hospital has enrolled four patients to date.
SPONSOR: Genervon Biopharmaceuticals, LLC
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS) 4
ABSTRACT: A Phase 3 clinical trial evaluating the administration of vampire bat venom, or intravenous Desmoteplase, given three to nine hours after acute ischemic stroke in patients based on selected MRI findings. The hope is that a higher rate of reperfusion and better clinical outcomes can be achieved. This is similar to tPA, the clot-busting drug, but within an expanded the treatment window. This trial is regarded as the single most important stroke trial going on internationally. This trial is active at Huntington Hospital and we are awaiting our first patient enrollment.
SPONSOR: H. Lundbeck A/S (Lead)
Ethnic/Racial Variations of Intracerebral Hemorrhage (ERICH)
ABSTRACT: A clinical trial exploring attempts to identify genetic and other predisposing factors for intracranial hemorrhage in African Americans and Hispanics. We are collaborating with USC on this clinical trial.
SPONSORS: University of Cincinnati (Lead),
National Institute of Neurological Disorders and Stroke (NINDS), University of Southern California
For more information on any of these trial, please call the office of Dr. Arbi Ohanian at (626) 535-9344
or our Clinical Research department at (626) 397-3877
To read our Conflict of Interest Disclosure policy, please click HERE